Cargando…
Amiodarone use and the risk of acute pancreatitis: Influence of different exposure definitions
PURPOSE: The antiarrhythmic drug amiodarone has a long half‐life of 60 days, which is often ignored in observational studies. This study aimed to investigate the impact of different exposure definitions on the association between amiodarone use and the risk of acute pancreatitis. METHOD: Using data...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6916315/ https://www.ncbi.nlm.nih.gov/pubmed/31373736 http://dx.doi.org/10.1002/pds.4851 |
_version_ | 1783480207506669568 |
---|---|
author | Hempenius, Mirjam Groenwold, Rolf H.H. de Boer, Anthonius Klungel, Olaf H. Gardarsdottir, Helga |
author_facet | Hempenius, Mirjam Groenwold, Rolf H.H. de Boer, Anthonius Klungel, Olaf H. Gardarsdottir, Helga |
author_sort | Hempenius, Mirjam |
collection | PubMed |
description | PURPOSE: The antiarrhythmic drug amiodarone has a long half‐life of 60 days, which is often ignored in observational studies. This study aimed to investigate the impact of different exposure definitions on the association between amiodarone use and the risk of acute pancreatitis. METHOD: Using data from the Dutch PHARMO Database Network, incident amiodarone users were compared to incident users of a different type of antiarrhythmic drug. Eighteen different definitions were applied to define amiodarone exposure, including dichotomized, continuous and categorized cumulative definitions with lagged effects to account for the half‐life of amiodarone. For each exposure definition, a Cox proportional hazards model was used to estimate the hazard ratio (HR) of hospitalization for acute pancreatitis. RESULTS: This study included 15,378 starters of amiodarone and 21,394 starters of other antiarrhythmic drugs. Adjusted HRs for acute pancreatitis ranged between 1.21−1.43 for dichotomized definitions of exposure to amiodarone, between 1.13‐1.22 for dose definitions (per DDD) and between 0.52‐1.72 for cumulative dose definitions, depending on the category. Accounting for lagged effects had little impact on estimated HRs. CONCLUSIONS: This study demonstrates the relative insensitivity of the association between amiodarone and the risk of acute pancreatitis against a broad range of different exposure definitions. Accounting for possible lagged effects had little impact, possibly because treatment switching and discontinuation was uncommon in this population. |
format | Online Article Text |
id | pubmed-6916315 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-69163152019-12-17 Amiodarone use and the risk of acute pancreatitis: Influence of different exposure definitions Hempenius, Mirjam Groenwold, Rolf H.H. de Boer, Anthonius Klungel, Olaf H. Gardarsdottir, Helga Pharmacoepidemiol Drug Saf Original Reports PURPOSE: The antiarrhythmic drug amiodarone has a long half‐life of 60 days, which is often ignored in observational studies. This study aimed to investigate the impact of different exposure definitions on the association between amiodarone use and the risk of acute pancreatitis. METHOD: Using data from the Dutch PHARMO Database Network, incident amiodarone users were compared to incident users of a different type of antiarrhythmic drug. Eighteen different definitions were applied to define amiodarone exposure, including dichotomized, continuous and categorized cumulative definitions with lagged effects to account for the half‐life of amiodarone. For each exposure definition, a Cox proportional hazards model was used to estimate the hazard ratio (HR) of hospitalization for acute pancreatitis. RESULTS: This study included 15,378 starters of amiodarone and 21,394 starters of other antiarrhythmic drugs. Adjusted HRs for acute pancreatitis ranged between 1.21−1.43 for dichotomized definitions of exposure to amiodarone, between 1.13‐1.22 for dose definitions (per DDD) and between 0.52‐1.72 for cumulative dose definitions, depending on the category. Accounting for lagged effects had little impact on estimated HRs. CONCLUSIONS: This study demonstrates the relative insensitivity of the association between amiodarone and the risk of acute pancreatitis against a broad range of different exposure definitions. Accounting for possible lagged effects had little impact, possibly because treatment switching and discontinuation was uncommon in this population. John Wiley and Sons Inc. 2019-08-02 2019-12 /pmc/articles/PMC6916315/ /pubmed/31373736 http://dx.doi.org/10.1002/pds.4851 Text en © 2019 The Authors. Pharmacoepidemiology & Drug Safety Published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Reports Hempenius, Mirjam Groenwold, Rolf H.H. de Boer, Anthonius Klungel, Olaf H. Gardarsdottir, Helga Amiodarone use and the risk of acute pancreatitis: Influence of different exposure definitions |
title | Amiodarone use and the risk of acute pancreatitis: Influence of different exposure definitions |
title_full | Amiodarone use and the risk of acute pancreatitis: Influence of different exposure definitions |
title_fullStr | Amiodarone use and the risk of acute pancreatitis: Influence of different exposure definitions |
title_full_unstemmed | Amiodarone use and the risk of acute pancreatitis: Influence of different exposure definitions |
title_short | Amiodarone use and the risk of acute pancreatitis: Influence of different exposure definitions |
title_sort | amiodarone use and the risk of acute pancreatitis: influence of different exposure definitions |
topic | Original Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6916315/ https://www.ncbi.nlm.nih.gov/pubmed/31373736 http://dx.doi.org/10.1002/pds.4851 |
work_keys_str_mv | AT hempeniusmirjam amiodaroneuseandtheriskofacutepancreatitisinfluenceofdifferentexposuredefinitions AT groenwoldrolfhh amiodaroneuseandtheriskofacutepancreatitisinfluenceofdifferentexposuredefinitions AT deboeranthonius amiodaroneuseandtheriskofacutepancreatitisinfluenceofdifferentexposuredefinitions AT klungelolafh amiodaroneuseandtheriskofacutepancreatitisinfluenceofdifferentexposuredefinitions AT gardarsdottirhelga amiodaroneuseandtheriskofacutepancreatitisinfluenceofdifferentexposuredefinitions |